Literature DB >> 10213220

Microsatellite instability is uncommon in breast cancer.

R Anbazhagan1, H Fujii, E Gabrielson.   

Abstract

In some tumors, defects in mismatch repair enzymes lead to errors in the replication of simple nucleotide repeat segments. This condition is commonly known as microsatellite instability (MSI) because of the frequent mutations of microsatellite sequences. Although the MSI phenotype is well recognized in some colon, gastric, pancreatic, and endometrial cancers, reports of MSI in breast cancer are inconsistent. We report here our experience with >10,000 amplifications of simple nucleotide repeats in noncoding genomic regions using DNA from 267 cases of breast cancer, including cases that represent all major histological types of breast cancer. We rarely (10 reactions) found unexpected bands in amplifications of tumor DNA that were not present in amplifications of normal DNA. Moreover, repeats of these reactions did not confirm microsatellite instability in a single case. We also evaluated the simple nucleotide repeats in the transforming growth factor type II receptor, insulin-like growth factor type II receptor, BAX, and E2F-4 genes, which are frequently mutated in tumors with microsatellite instability. No mutations of these genes were found in any of the 30 breast cancer cell lines and 61 primary breast cancer samples examined. These results indicate that mismatch repair errors characteristic of the MSI phenotype are uncommon in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213220

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

2.  Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies.

Authors:  Ekatherina Sh Kuligina; Maxim Yu Grigoriev; Evgeny N Suspitsin; Konstantin G Buslov; Olga A Zaitseva; Olga S Yatsuk; Yulia R Lazareva; Alexandr V Togo; Evgeny N Imyanitov
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-10       Impact factor: 4.553

3.  Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis.

Authors:  Shiquan Liu; Wenjing Liu; John L Jakubczak; Gregory L Erexson; Kenneth R Tindall; Richard Chan; William J Muller; Sankar Adhya; Susan Garges; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

4.  Gene promoter hypermethylation in tumors and plasma of breast cancer patients.

Authors:  Young Kyung Bae; Young Ran Shim; Joon Hyuk Choi; Mi Jin Kim; Edward Gabrielson; Soo Jung Lee; Tae Yoon Hwang; Sei One Shin
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

Review 5.  Checkpoint Inhibitors in the Treatment of Breast Cancer.

Authors:  Tomas G Lyons; Maura N Dickler; Elizabeth E Comen
Journal:  Curr Oncol Rep       Date:  2018-04-30       Impact factor: 5.075

6.  Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.

Authors:  Carlo Fremd; Mario Hlevnjak; Marc Zapatka; Inka Zoernig; Niels Halama; Nino Fejzibegovic; Verena Thewes; Peter Lichter; Peter Schirmacher; Matthias Kloor; Frederik Marmé; Florian Schütz; Zeynep Kosaloglu; Hans Peter Sinn; Dirk Jäger; Andreas Schneeweiss
Journal:  Breast Care (Basel)       Date:  2018-11-14       Impact factor: 2.860

7.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

Review 8.  Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.

Authors:  Sabine Grill; Evelyn Klein
Journal:  Breast Care (Basel)       Date:  2021-01-20       Impact factor: 2.860

Review 9.  The molecular background of mucinous carcinoma beyond MUC2.

Authors:  Niek Hugen; Michiel Simons; Altuna Halilović; Rachel S van der Post; Anna J Bogers; Monica Aj Marijnissen-van Zanten; Johannes Hw de Wilt; Iris D Nagtegaal
Journal:  J Pathol Clin Res       Date:  2014-11-05

10.  The absence of Mth1 inactivation and DNA polymerase kappa overexpression in rat mammary carcinomas with frequent A:T to C:G transversions.

Authors:  Eriko Okochi; Shizue Ichimura; Takashi Sugimura; Toshikazu Ushijima
Journal:  Jpn J Cancer Res       Date:  2002-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.